



# Consolidated Financial Results for the Six Months Ended September 30, 2025 [IFRS]

November 12, 2025

Company Name: PHC HOLDINGS CORPORATION

Stock Code: 6523 (URL: <https://www.phchd.com/global/ir>)

Stock Exchange Listing: Tokyo

Representative: Kyoko Deguchi, Chief Executive Officer

Contact: Masashi Kimura, Executive General Manager of Corporate Administration Department

Phone: +81-3-5408-7280

Scheduled date to submit the Semi-Annual Securities Report: November 12, 2025

Scheduled date to commence dividend payments: December 18, 2025

Availability of supplementary briefing material on the Semi-Annual Results: Yes

Scheduled date of the Semi-Annual Results Briefing Session: Yes

(Figures are rounded down to the nearest million yen)

## 1. Consolidated Financial Results for the Six Months Ended September 30, 2025 (From April 1, 2025 to September 30, 2025)

### (1) Consolidated Results of Operations

(% indicates changes from the previous corresponding term)

	Revenue		Operating profit		Profit before taxes		Profit		Profit attributable to owners of parent		Comprehensive income	
Six months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2025	173,375	(0.3)	10,378	12.7	941	(87.3)	(692)	-	(559)	-	7,236	-
September 30, 2024	173,863	4.2	9,212	120.3	7,411	-	4,022	-	4,100	-	(9,626)	-

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2025	(4.42)	(4.42)
September 30, 2024	32.52	32.42

(Note) Share of profit (loss) of investments accounted for using equity method:

September 30, 2025... 67 million yen

September 30, 2024... (162) million yen

## (2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
As of	Millions of yen	Millions of yen	Millions of yen	%
September 30, 2025	525,819	146,041	146,658	27.9
March 31, 2025	532,482	141,171	141,639	26.6

## 2. Cash Dividends

	Annual cash dividends per share				
	First quarter end	Second quarter end	Third quarter end	Fiscal year end	Total
Fiscal year ended	Yen	Yen	Yen	Yen	Yen
March 31, 2025	—	21.00	—	21.00	42.00
March 31, 2026	—	21.00			
Fiscal year ending March 31, 2026 (Forecast)			—	21.00	42.00

(Note) Revision of cash dividends forecasts to the latest announcement: None

## 3. Forecast of Consolidated Financial Results for the Year Ending March 31, 2026 (From April 1, 2025 to March 31, 2026)

(% indicates year-on-year changes)

	Revenue		Operating profit		Profit before taxes		Profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	
Fiscal year ending March 31, 2026	363,100	0.4	20,000	(11.4)	8,000	(57.5)	4,500	(56.6)	4,400	(58.0)	Yen 34.80

(Note) Revision of consolidated earnings forecasts to the latest announcement: Yes

**\* Notes**

(1) Changes in significant subsidiaries during the current period (Changes in specific subsidiaries involving changes in the scope of consolidation): None

Newly included: - companies

Excluded: - companies

(2) Changes in accounting policies, changes in accounting estimates

1) Changes in accounting policies required by IFRS: Not applicable

2) Changes in accounting policies other than 1) : Not applicable

3) Changes in accounting estimates: Not applicable

(3) Total number of issued shares (common stock):

1) Total number of issued shares at the end of the period (including treasury shares):

As of September 30, 2025	126,721,820 Shares
As of March 31, 2025	126,410,072 Shares

2) Total number of treasury shares at the end of the period:

As of September 30, 2025	211,941 Shares
As of March 31, 2025	211,941 Shares

3) Average number of outstanding shares during the period:

Six months ended September 30, 2025	126,382,905 Shares
Six months ended September 30, 2024	126,096,069 Shares

Note 1: Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

Note 2: Explanation regarding proper use of the projected financial results and other notes:

The forecasted statements shown in these materials are based on information currently available and certain assumptions that PHC Holdings Corporation regards as reasonable, and therefore the group's actual results may differ materially due to unknown several factors.

Contents of attached documents:

1. Qualitative information regarding financial performance	
(1) Explanation regarding operation results	5
(2) Explanation regarding financial condition position (Balance Sheet)	13
(3) Explanation regarding cash flow	13
(4) Explanation regarding future prospects (ex. forecasted consolidated business results)	14
2. Condensed semi-annual consolidated financial statement and significant notes	
(1) Condensed semi-annual consolidated statement of financial position	16
(2) Condensed semi-annual consolidated statement of profit or loss and condensed semi-annual consolidated statement of comprehensive income	18
(3) Condensed semi-annual consolidated statement of changes in equity	20
(4) Condensed semi-annual consolidated statement of cash flows	22
(5) Notes to condensed semi-annual consolidated financial statements	23
Notes for going concern	23
Segment information	23
Revenue	25

## 1. Qualitative information regarding financial performance

### (1) Explanation regarding operation results

During the six months ended September 30, 2025 (hereafter “this period”), PHC Group generated revenue of JPY 173,375 million, down 0.3% compared to the same period of the previous year (hereafter “year on year”). In Diabetes Management, revenue was on par year on year. But excluding the FX impact, revenue increased slightly. In Healthcare Solutions, despite a decline in revenue from CRO business, overall revenue grew by increased volume of genetic testing in LSIM business and encouraging results in revenue from the business related to electronic medical records and medical-receipt systems in Healthcare IT Solutions. In Diagnostics & Life Sciences, revenue decreased mainly due to the appreciation of the yen against USD and the impact of stagnant market conditions, particularly in the U.S.

Operating profit for this period was JPY 10,378 million, up 12.7% year on year. In Diabetes Management, operating profit increased significantly due to the strong performance of Blood Glucose Monitoring (hereafter “BGM”) business, mainly in developed countries. In Healthcare Solutions, operating profit declined due to the weaker demand for high-margin electronic prescriptions software and the impact of decreased revenue in CRO business. Diagnostics & Life Sciences also saw a decline in operating profit due to lower revenues in Biomedical (PHCbi) business and In Vitro Diagnostics (hereafter “IVD”) business, and the impact of transferring some of corporate functions described below.

Adjusted EBITDA was JPY 24,260 million, up 4.2% year on year. Adjustment items include one-time income/expense relating to restructuring (additions of JPY 452 million in this period and JPY 315 million in the same period of the previous fiscal year, hereafter “the previous period”) and one-time income/expense relating to transformational M&A pre-acquisition and integration costs (additions of JPY 80 million in this period and JPY 25 million in the previous period).

Profit before tax was JPY 941 million, down 87.3% year on year. Despite a decrease in interest expenses, this decline was due to foreign exchange losses of JPY 6,842 million recorded during this period, compared to foreign exchange gains of JPY 1,210 million in the previous period.

Loss attributable to owners of parent was JPY 559 million (Profit of JPY 4,100 million in the previous period) due to the recorded corporate income tax expenses of JPY 1,634 million.

Please note that, starting from this period, we have reviewed corporate functions and transferred some headquarters roles to each business. While this review does not affect the consolidated financial results, it does have an impact on profit by segment. The impact on actual results for this period is described in the operating profit and adjusted EBITDA for each segment.

	Six months ended September 30, 2024 (million yen)	Six months ended September 30, 2025 (million yen)	Change
Revenue	173,863	173,375	(0.3%)
Operating profit	9,212	10,378	12.7%
EBITDA	23,579	23,727	0.6%
Adjusted EBITDA	23,293	24,260	4.2%
Profit before tax	7,411	941	(87.3%)
Profit (loss)	4,022	(692)	—
Profit (loss) attributable to owners of parent	4,100	(559)	—
Average exchange rate JPY/USD	JPY 152.51	JPY 145.96	JPY (6.55)
Average exchange rate JPY/EUR	JPY 165.86	JPY 168.13	JPY 2.27

(Note) EBITDA and Adjusted EBITDA are not measures in accordance with IFRS. However, PHC Holdings Corporation believes that this disclosure may be useful information to investors.

【Calculation table of EBITDA and adjusted EBITDA】

	Six months ended September 30, 2024 (million yen)	Six months ended September 30, 2025 (million yen)	Change
Operating profit	9,212	10,378	12.7%
+ Depreciation	14,310	13,347	(6.7%)
+ Impairment loss (excluding marketable securities)	56	1	(98.2%)
EBITDA	23,579	23,727	0.6%
(Adjusted amount)			
+ One-time income/expense relating to transformational M&A pre-acquisition and integration costs	25	80	220.0%
+ One-time income/expense relating to restructuring	315	452	43.5%
+ One-time income/expense relating to disposal/sales of asset	—	—	—
+ Other one-time income/expense	(627)	—	—
Adjusted EBITDA	23,293	24,260	4.2%

(Note) EBITDA and adjusted EBITDA are calculated with the following formulas:

EBITDA = Operating profit + depreciation + impairment loss (excluding marketable securities)

Adjusted EBITDA = EBITDA + one-time income and expenses

The business performance by segment is as follows:

**Diabetes Management**

	Six months ended September 30, 2024 (million yen)	Six months ended September 30, 2025 (million yen)	Change
Revenue	48,259	48,678	0.9%
Operating profit	6,361	9,328	46.6%
EBITDA	9,741	11,552	18.6%
Adjusted EBITDA	9,848	11,744	19.3%

(Calculation table of EBITDA and adjusted EBITDA)

	Six months ended September 30, 2024 (million yen)	Six months ended September 30, 2025 (million yen)	Change
Operating profit	6,361	9,328	46.6%
+ Depreciation	3,323	2,224	(33.1%)
+ Impairment loss (excluding marketable securities)	56	—	—
EBITDA	9,741	11,552	18.6%
(Adjustment amount)			
+ One-time income/expense relating to transformational M&A pre-acquisition and integration costs	—	—	—
+ One-time income/expense relating to restructuring	106	192	81.1%
+ One-time income/expense relating to disposal/sales of asset	—	—	—
+ Other one-time income/expense	—	—	—
Adjusted EBITDA	9,848	11,744	19.3%

(Note) EBITDA and adjusted EBITDA are calculated with the following formulas:

EBITDA = Operating profit + depreciation + impairment loss (excluding marketable securities)

Adjusted EBITDA = EBITDA + one-time income and expenses

<Revenue Situation>

Revenue of Diabetes Management for this period was JPY 48,678 million, up 0.9% year on year. Despite ongoing market contraction and the shift to low-priced channels in developed markets, BGM business performed strongly due to the reduced impact of the termination of sales collaboration and the success of initiatives that improved unit prices and increased sales volumes in the U.S. In Europe, solid performance also contributed to the positive results. Additionally, in Continuous Glucose Monitoring (hereafter “CGM”) business, revenue increased in the U.S. due to Eversense 365 system, which was launched during the third quarter of the previous consolidated fiscal year and allows users one year of uninterrupted use.

<Operating Profit and Adjusted EBITDA Situation>

The operating profit of Diabetes Management for this period was JPY 9,328 million, up 46.6% year on year. Despite a negative impact of JPY 143 million due to the earlier-mentioned transfer of some corporate functions, this was due to a significant profit increase in BGM business, driven by sales in developed countries, improved profit margins by profit improvement and price initiatives, the cost reduction with restructuring to date, and a lower depreciation expenses.

Adjusted EBITDA was JPY 11,744 million, up 19.3% year on year. Adjustment items included one-time income/expense relating to restructuring (additions of JPY 192 million in this period and JPY 106 million in the previous period, respectively).



## Healthcare Solutions

	Six months ended September 30, 2024 (million yen)	Six months ended September 30, 2025 (million yen)	Change
Revenue	61,484	62,653	1.9%
Operating profit	3,635	2,970	(18.3%)
EBITDA	8,620	8,175	(5.2%)
Adjusted EBITDA	8,646	8,256	(4.5%)

### (Calculation table of EBITDA and adjusted EBITDA)

	Six months ended September 30, 2024 (million yen)	Six months ended September 30, 2025 (million yen)	Change
Operating profit	3,635	2,970	(18.3%)
+ Depreciation	4,984	5,205	4.4%
+ Impairment loss (excluding marketable securities)	—	—	—
EBITDA	8,620	8,175	(5.2%)
(Adjustment amount)			
+ One-time income/expense relating to transformational M&A pre-acquisition and integration costs	25	80	220.0%
+ One-time income/expense relating to restructuring	—	—	—
+ One-time income/expense relating to disposal/sales of asset	—	—	—
+ Other one-time income/expense	—	—	—
Adjusted EBITDA	8,646	8,256	(4.5%)

(Note) EBITDA and adjusted EBITDA are calculated with the following formulas:

EBITDA = Operating profit + depreciation + impairment loss (excluding marketable securities)

Adjusted EBITDA = EBITDA + one-time income and expenses

### <Revenue Situation>

Revenue of Healthcare Solutions for this period was JPY 62,653 million, up 1.9% year on year. A breakdown includes LSIM business at JPY 33,613 million, up 2.0% year on year, Healthcare IT Solutions business at JPY 25,774 million, up 6.1% year on year, and CRO business at JPY 3,265 million, down 23.0% year on year.

In LSIM business, revenue increased slightly due mainly to the sales increase of genetic testing, one of LSIM's growth initiatives.

In Healthcare IT Solutions, robust sales related to electronic medical record and medical-receipt systems offset the impact of lower demand for electronic prescription software, resulting in increased revenue.

In CRO business, revenue declined as in the previous period large-scale safety testing in the non-clinical testing business completed.

<Operating Profit and Adjusted EBITDA Situation>

Operating profit in Healthcare Solutions for this period was JPY 2,970 million, down 18.3% year on year. In LSIM business, profit grew through higher revenue and cost reduction efforts. However, operating profit declined due to lower demand for high-margin electronic prescription software and increased depreciation costs and rising purchase prices for IT equipment among other factors in Healthcare IT Solutions business, and lower revenue in CRO business. The reduction due to the earlier-mentioned transfer of some corporate functions was JPY 41 million.

Adjusted EBITDA was JPY 8,256 million, down 4.5% year on year. Adjustment items include one-time income/expense relating to transformational M&A pre-acquisition and integration costs (additions of JPY 80 million in this period and JPY 25 million in the previous period, respectively).

## Diagnostics and Life Sciences

	Six months ended September 30, 2024 (million yen)	Six months ended September 30, 2025 (million yen)	Change
Revenue	62,561	59,142	(5.5%)
Operating profit	3,494	1,317	(62.3%)
EBITDA	9,156	6,933	(24.3%)
Adjusted EBITDA	8,647	6,935	(19.8%)

(Calculation table of EBITDA and adjusted EBITDA)

	Six months ended September 30, 2024 (million yen)	Six months ended September 30, 2025 (million yen)	Change
Operating profit	3,494	1,317	(62.3%)
+ Depreciation	5,661	5,615	(0.8%)
+ Impairment loss (excluding marketable securities)	—	1	—
EBITDA	9,156	6,933	(24.3%)
(Adjustment amount)			
+ One-time income/expense relating to transformational M&A pre-acquisition and integration costs	—	—	—
+ One-time income/expense relating to restructuring	122	2	(98.4%)
+ One-time income/expense relating to disposal/sales of asset	—	—	—
+ Other one-time income/expense	(631)	—	—
Adjusted EBITDA	8,647	6,935	(19.8%)

(Note) EBITDA and adjusted EBITDA are calculated with the following formulas:

EBITDA = Operating profit + depreciation + impairment loss (excluding marketable securities)

Adjusted EBITDA = EBITDA + one-time income and expenses

### <Revenue Situation>

Revenue of Diagnostics and Life Sciences for this period was JPY 59,142 million, down 5.5% year on year. This includes JPY 27,732 million in Pathology business, down 1.8% year on year, JPY 22,864 million in Biomedical (PHCbi) business, down 6.0% year on year, and JPY 8,545 million in IVD business, down 14.7% year on year. In Pathology business, excluding the FX impact, revenue was on par year on year. Revenue declined in the Americas due to continued softness in equipment demand. On the other hand, Europe achieved revenue growth, driven by the steady performance of microscope slides and consumables, as well as the acquisition of large-scale projects for digital pathology products during the first quarter of this consolidated fiscal year. In Asia Pacific, revenue increased supported by the modest recovery in China related to portfolio expansion as part of the China for China manufacturing transfer project which included the start of digital pathology manufacturing as well. In Biomedical (PHCbi) business, revenue decreased due to the appreciated yen against USD and lower demand caused by U.S. policies, despite signs of recovery in Europe, Japan, and other areas. In the Americas, demand remains slow due to ongoing budget cuts at US government agencies, universities, and research institutions, as well as frequent delays in biopharmaceutical-related and small-to-medium-sized projects. In EMEA, despite the negative effects of investment halts and R&D pullbacks by major pharmaceutical companies in the UK caused by policy concerns, revenue increased due to strong performance in France, the Middle East, and other regions. In Japan, revenue growth was driven by large-scale projects, including the construction of new university research

buildings.

In IVD business, revenue declined mainly due to lower sales of reagents for PATHFAST™ Immunoanalyzer and automated analyzers in Russia, as well as the lower demand in China with reduced numbers of testing.

Additionally, the decline in sales of digital injectors and the absence of one-time revenue recorded in the previous period contributed to the decrease.

<Operating Profit and Adjusted EBITDA Situation>

Operating Profit in Diagnostics and Life Sciences for this period was JPY 1,317 million, down 62.3% year on year. While Pathology business was driven by the positive effect of price revisions and the record of other income due to changes in the classification of affiliated companies, Biomedical and IVD businesses were unable to absorb the impact of lower revenues by cost down initiatives and other efforts. Additionally, the reduction of JPY 551 million due to the earlier-mentioned transfer of some corporate functions, the absence of one-time income recorded in IVD business during the previous period, and approx. JPY 800 million the tariff impacts were main contributing factors to the lower operating profit.

Adjusted EBITDA was JPY 6,935 million, down 19.8% year on year. Adjustment items include one-time income/expense relating to restructuring (additions of JPY 2 million in this period and JPY 122 million in the previous period, respectively).

## (2) Explanation regarding financial condition position (Balance Sheet)

### Asset

The balance of total assets in the second quarter of this fiscal year was JPY 525,819 million. The balance decreased by JPY 6,663 million compared to the previous fiscal year-end. The balance decrease primarily reflects a cash and cash equivalents decrease of JPY 6,283 million, mainly due to loan repayment and distribution of dividends, and property, plant and equipment decrease of JPY 4,088 million, mainly due to progress in depreciation, and other financial assets decrease of JPY 2,582 million mainly due to the market valuation of securities. On the other hand, goodwill increased by JPY 5,600 million, due to the impact of weakened yen.

### Liability

The balance of total liabilities in the second quarter of this fiscal year was JPY 379,777 million. The balance decreased by JPY 11,533 million compared to the previous fiscal year-end. The main reason is, borrowings decreased by net amount JPY 7,569 million primarily due to loan repayments and on the other hand increased due to the impact of weakened yen. In addition, other financial liabilities decreased by JPY 3,751 million.

### Equity

The balance of equity in the second quarter of this fiscal year was JPY 146,061 million. The balance increased by JPY 4,869 million compared to the previous fiscal year-end. Other components of equity increased by JPY 7,732 million, mainly due to translation difference of foreign operations. On the other hand, retained earnings decreased by JPY 2,946 million mainly due to JPY 559 million of loss attributable to owners of parent and JPY 2,650 million of dividends.

In addition, the ratio of equity attributable to owners of parent to total assets increased by 1.3 points from 26.6% at the end of the previous fiscal year to 27.9%.

## (3) Explanation regarding cash flow

Cash and cash equivalents at the end of the period amounted to JPY 33,309 million, a decrease of JPY 6,283 million from March 31, 2025.

The status of each cash flows from each activity and its drivers during this period are as follows:

### (Cash flows from operating activities)

Net cash provided by operating activities was JPY 12,086 million, which was a decrease of JPY 1,681 million year on year.

### (Cash flows from investing activities)

Net cash used in investing activities was JPY 4,242 million and consisted mainly of purchase of property, plant, and equipment, and intangible assets of JPY 4,380 million. The decrease in net cash used in investing activities of JPY 741 million year on year was mainly due to a decrease in purchase of property, plant, and equipment, and intangible assets.

### (Cash flows from financing activities)

Net cash used in financing activities of JPY 17,562 million consisted mainly of repayments of long-term borrowings of JPY 13,937 million, proceeds from long-term borrowings of JPY 2,999 million and repayments of lease liabilities of JPY 2,963 million. The decrease in net cash used in financing activities of JPY 3,358 million year on year was mainly due to proceeds from long-term borrowings of JPY 2,999 million.

(4) Explanation regarding future prospects (ex. forecasted consolidated business results)

Revisions to consolidated financial results forecasts for the fiscal year ending March 31, 2026 (April 1, 2025 through March 31, 2026)

	Revenue (Million JPY)	Operating profit (Million JPY)	Profit before tax (Million JPY)	Profit (Million JPY)	Profit attributable to owners of parent (Million JPY)	Basic earnings per share attributable to owners of parent (JPY)	*Adjusted EBITDA (Million JPY)
Previously announced forecasts (A)	363,100	17,400	12,200	7,400	7,400	58.64	45,200
Revised forecasts (B)	363,100	20,000	8,000	4,500	4,400	34.80	47,800
Change (B-A)	—	2,600	(4,200)	(2,900)	(3,000)	(23.84)	2,600
Change (%)	—	14.9	(34.4)	(39.2)	(40.5)	(40.7)	5.8
(Reference) Consolidated results for the previous fiscal year (Fiscal year ended March 31, 2025)	361,593	22,580	18,823	10,364	10,485	83.13	50,095

(Note) Adjusted EBITDA is calculated with the following formula:

Adjusted EBITDA = EBITDA + one-time income and expenses

EBITDA = Operating profit + depreciation + impairment loss (excluding marketable securities)

\*Adjusted EBITDA is not a measure in accordance with IFRS. However, PHC Holdings Corporation believes that this disclosure may be useful information to investors.

The exchange rates underlying the full-year financial forecast have been revised, considering the current rates, from JPY 155 to JPY 171 per euro and from JPY 140 to JPY 146 per US dollar.

Regarding the transfer of the CGM business (the commercial operation of Eversense), which was announced in the "Notice Regarding the Signing of the Memorandum of Understanding on the Business Transfer of a Consolidated Subsidiary" as of September 4, 2025, though negotiations toward the signing of the Definitive Agreement are ongoing, the expected impact has been incorporated reasonably at this point of time.

Additionally, concerning the indication of goodwill impairment in the Diabetes Management segment mentioned in the aforementioned timely disclosure, an impairment test has been conducted, and it has been determined that there is no need for impairment at this stage.

Revenue, in total, remains unchanged from the previously announced forecast. In the Diabetes Management segment, on the assumption that the CGM business will be excluded from consolidation from the fourth quarter as planned, the forecast has been revised upward, reflecting an upward revision of the BGM business, which continues to perform strongly, including the positive impact of the exchange rate changes. In the HQ and Others segment, the forecast has also been revised upward, incorporating the elimination of risks initially anticipated. On the other hand, the Healthcare Solutions segment has been revised downward, reflecting the order status of the CRO business. Also the Diagnostics & Life Sciences segment has been revised downward, reflecting the assumption that weak demand for equipment will continue, primarily due to the reduction of government subsidies in the U.S. and other factors.

Operating profit has been revised upward by JPY 2.6 billion from the previously announced forecast. While the Diagnostics & Life Sciences segment has been revised downward to reflect the impact of reduced revenue, the Diabetes Management segment has been revised upward with both the impact of the exclusion of the CGM business from consolidation and the increased revenue from the BGM business. Additionally, the HQ and Others segment has also been revised upward, reflecting the impact of increased revenue as well as a review of one-time expenses.

Whereas, due to JPY 6.8 billion of foreign exchange losses recorded during the first six months, profit before tax has been revised downward by JPY 4.2 billion, and profit attributable to owners of parent has been

revised downward by JPY 3.0 billion with reduction in tax expenses by JPY 1.2 billion.

Forecasts of business performance by segment are as follows:

Segments	Revenue (Million JPY)		Operating profit(loss) (Million JPY)		Adjusted EBITDA (Million JPY)	
	Before Change	After Change	Before Change*	After Change	Before Change*	After Change
Diabetes Management	96,200	99,000	14,000	18,200	18,800	23,400
Healthcare Solutions	132,300	131,300	8,100	8,100	18,800	18,800
Diagnostics and Life Sciences	133,700	128,100	5,600	3,000	16,300	13,700
Head office and Others	1,000	4,800	(10,400)	(9,300)	(8,700)	(8,100)
Total	363,100	363,100	17,400	20,000	45,200	47,800

\*Starting this fiscal year, the Company reviewed its headquarters' functions and transferred some of the headquarters' roles to each business division. As a result, the breakdown of operating profit and adjusted EBITDA by segment was revised on August 7, 2025.

## 2. Condensed semi-annual consolidated financial statement and significant notes

### (1) Condensed semi-annual consolidated statement of financial position

(Unit: million yen)

	As of March 31, 2025	As of September 30, 2025
Assets		
Current assets		
Cash and cash equivalents	39,592	33,309
Trade receivables	70,530	65,370
Inventories	51,694	57,897
Other financial assets	4,308	3,544
Other current assets	6,665	8,935
Total current assets	172,790	169,056
Non-current assets		
Property, plant and equipment	48,374	44,286
Goodwill	206,500	212,100
Intangible assets	80,649	76,688
Investments accounted for using equity method	1,821	1,006
Other financial assets	13,932	12,113
Deferred tax assets	6,120	8,183
Other non-current assets	2,293	2,382
Total non-current assets	359,691	356,762
Total assets	532,482	525,819



(Unit: million yen)

	As of March 31, 2025	As of September 30, 2025
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	65,665	67,093
Borrowings	34,278	245,011
Income taxes payable	4,207	3,350
Provisions	7,725	7,759
Other financial liabilities	5,812	5,309
Other current liabilities	22,865	19,113
Total current liabilities	140,555	347,637
Non-current liabilities		
Trade and other payables	597	597
Borrowings	220,982	2,680
Retirement benefit liability	5,544	5,748
Provisions	4,575	4,599
Other financial liabilities	8,358	7,022
Deferred tax liabilities	9,291	10,040
Other non-current liabilities	1,405	1,450
Total non-current liabilities	250,755	32,140
Total liabilities	391,310	379,777
Equity		
Share capital	48,623	48,781
Capital surplus	42,039	42,114
Retained earnings	2,991	44
Treasury shares	(568)	(568)
Other components of equity	48,553	56,286
Equity attributable to owners of parent	141,639	146,658
Non-controlling interests	(468)	(617)
Total equity	141,171	146,041
Total liabilities and equity	532,482	525,819

(2) Condensed semi-annual consolidated statement of profit or loss and condensed semi-annual consolidated statement of comprehensive income  
(Condensed semi-annual consolidated statement of profit or loss)

(Unit: million yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Revenue	173,863	173,375
Cost of sales	92,635	93,781
Gross profit	81,227	79,594
Selling, general and administrative expenses	72,071	70,018
Other income	384	1,073
Other expenses	166	337
Share of profit (loss) of investments accounted for using equity method	(162)	67
Operating profit	9,212	10,378
Finance income	1,414	169
Finance costs	3,215	9,606
Profit (loss) before taxes	7,411	941
Income tax expense	3,389	1,634
Profit (loss)	4,022	(692)
Profit (loss) attributable to		
Owners of parent	4,100	(559)
Non-controlling interests	(78)	(133)
Earnings (loss) per share		
Basic earnings (loss) per share (Unit: JPY)	32.52	(4.42)
Diluted earnings (loss) per share (Unit: JPY)	32.42	(4.42)

## (Condensed semi-annual consolidated statement of comprehensive income)

(Unit: million yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Profit (loss)	4,022	(692)
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Remeasurements of defined benefit plans	(770)	211
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income	(2,114)	(2,418)
Items that may be reclassified to profit or loss		
Effective portion of cash flow hedges	43	0
Exchange differences on translation of foreign operations	(10,709)	10,520
Share of other comprehensive income of investments accounted for using equity method	(97)	(383)
Other comprehensive income, net of taxes	(13,648)	7,928
Comprehensive income	(9,626)	7,236
Comprehensive income attributable to		
Owners of parent	(9,563)	7,385
Non-controlling interests	(62)	(148)
Comprehensive income	(9,626)	7,236

### (3) Condensed semi-annual consolidated statement of changes in equity

(Unit: million yen)

	Equity attributable to owners of parent					Other components of equity	
	Share capital	Capital surplus	Retained earnings	Treasury shares	Remeasurements of defined benefit plans	Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income	Effective portion of cash flow hedges
As of April 1, 2024	48,423	41,797	(2,773)	(568)	—	(1,110)	(3)
Comprehensive income							
Profit (loss)	—	—	4,100	—	—	—	—
Other comprehensive income	—	—	—	—	(770)	(2,114)	43
Total comprehensive income	—	—	4,100	—	(770)	(2,114)	43
Issuance of new shares	98	(61)	—	—	—	—	—
Dividends to owners of parent	—	—	(2,268)	—	—	—	—
Forfeiture of share acquisition rights and Restricted Stock Unit	—	(19)	16	—	—	—	—
Share-based payment transactions	—	86	—	—	—	—	—
Transfer from other components of equity to retained earnings	—	—	(916)	—	770	146	—
Transactions with owners	98	5	(3,168)	—	770	146	—
As of September 30, 2024	48,522	41,802	(1,841)	(568)	—	(3,078)	40

(Unit: million yen)

	Equity attributable to owners of parent					
	Other components of equity					
	Exchange differences on translation of foreign operations	Share of other comprehensive income of investments accounted for using equity method	Total	Total	Non-controlling interests	Total
As of April 1, 2024	53,380	369	52,635	139,515	(351)	139,163
Comprehensive income						
Profit (loss)	—	—	—	4,100	(78)	4,022
Other comprehensive income	(10,725)	(97)	(13,664)	(13,664)	16	(13,648)
Total comprehensive income	(10,725)	(97)	(13,664)	(9,563)	(62)	(9,626)
Issuance of new shares	—	—	—	36	—	36
Dividends to owners of parent	—	—	—	(2,268)	—	(2,268)
Forfeiture of share acquisition rights and Restricted Stock Unit	—	—	—	(2)	—	(2)
Share-based payment transactions	—	—	—	86	—	86
Transfer from other components of equity to retained earnings	—	—	916	—	—	—
Transactions with owners	—	—	916	(2,148)	—	(2,148)
As of September 30, 2024	42,654	271	39,887	127,803	(413)	127,389

(Unit: million yen)

	Equity attributable to owners of parent						
	Other components of equity						
	Share capital	Capital surplus	Retained earnings	Treasury shares	Remeasurements of defined benefit plans	Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income	
As of April 1, 2025	48,623	42,039	2,991	(568)	—	(233)	(17)
Comprehensive income							
Profit (loss)	—	—	(559)	—	—	—	—
Other comprehensive income	—	—	—	—	211	(2,418)	(0)
Total comprehensive income	—	—	(559)	—	211	(2,418)	(0)
Issuance of new shares	158	173	—	—	—	—	—
Dividends to owners of parent	—	—	(2,650)	—	—	—	—
Forfeiture of share acquisition rights and Restricted Stock Unit	—	(60)	51	—	—	—	—
Share-based payment transactions	—	(38)	—	—	—	—	—
Transfer from other components of equity to retained earnings	—	—	211	—	(211)	—	—
Transactions with owners	158	74	(2,387)	—	(211)	—	—
As of September 30, 2025	48,781	42,114	44	(568)	—	(2,651)	(18)

(Unit: million yen)

	Equity attributable to owners of parent					
	Other components of equity					
	Exchange differences on translation of foreign operations	Share of other comprehensive income of investments accounted for using equity method	Total	Total	Non-controlling interests	
As of April 1, 2025	48,447	357	48,553	141,639	(468)	141,171
Comprehensive income						
Profit (loss)	—	—	—	(559)	(133)	(692)
Other comprehensive income	10,535	(383)	7,944	7,944	(15)	7,928
Total comprehensive income	10,535	(383)	7,944	7,385	(148)	7,236
Issuance of new shares	—	—	—	331	—	331
Dividends to owners of parent	—	—	—	(2,650)	—	(2,650)
Forfeiture of share acquisition rights and Restricted Stock Unit	—	—	—	(9)	—	(9)
Share-based payment transactions	—	—	—	(38)	—	(38)
Transfer from other components of equity to retained earnings	—	—	(211)	—	—	—
Transactions with owners	—	—	(211)	(2,366)	—	(2,366)
As of September 30, 2025	58,983	(26)	56,286	146,658	(617)	146,041

## (4) Condensed semi-annual consolidated statement of cash flows

(Unit: million yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Cash flows from operating activities		
Profit (loss) before taxes	7,411	941
Depreciation and amortization	14,310	13,347
Interest expenses	3,077	2,665
Decrease (increase) in trade receivables	8,813	6,689
Decrease (increase) in inventories	(4,023)	(4,738)
Increase (decrease) in trade payables	(4,580)	537
Other	(7,705)	(658)
Subtotal	17,303	18,784
Interest and dividends received	205	97
Interest paid	(3,381)	(2,622)
Income taxes paid	(2,454)	(4,235)
Income taxes refund	2,093	62
Net cash provided by operating activities	13,767	12,086
Cash flows from investing activities		
Purchase of property, plant and equipment, and intangible assets	(5,897)	(4,380)
Proceeds from sales of property, plant and equipment, and intangible assets	206	277
Other	707	(139)
Net cash used in investing activities	(4,983)	(4,242)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	(1,523)	(998)
Proceeds from long-term borrowings	—	2,999
Repayments of long-term borrowings	(13,518)	(13,937)
Repayments of lease liabilities	(3,631)	(2,963)
Proceeds from issuance of shares	37	0
Dividends paid to owners of parent	(2,268)	(2,649)
Other	(14)	(13)
Net cash used in financing activities	(20,920)	(17,562)
Effect of exchange rate changes on cash and cash equivalents	(1,937)	3,435
Net increase (decrease) in cash and cash equivalents	(14,074)	(6,283)
Beginning balance of cash and cash equivalents	47,044	39,592
Ending balance of cash and cash equivalents	32,969	33,309

(5) Notes to condensed semi-annual consolidated financial statements

**Notes for going concern**

Not applicable

**Segment information**

1) Reportable segments

Major business contents in each reportable segment are as follows:

Reportable segments	Major business contents
Diabetes Management	Development, manufacturing, and sales of blood glucose monitoring (BGM) systems, and sales of continuous glucose monitoring (CGM) systems
Healthcare Solutions	Development of clinical testing business, development and sales of medical IT products such as medical-receipt computers and electronic medical record systems, and development of drug discovery support business
Diagnostics & Life Sciences	Development, manufacturing, and sales of pathological diagnosis equipment, research and medical support equipment, diagnostic reagents and instruments, as well as motorized drug injection devices

2) Segment revenues and operating results  
Six months ended September 30, 2024

(Unit: million yen)

	Diabetes Management	Healthcare Solutions	Diagnostic & Life Sciences	Subtotal	Others, adjustments and eliminations	Consolidated basis
Revenue						
Sale from external customers	48,259	61,484	62,561	172,305	1,557	173,863
Intersegment sales	—	—	—	—	—	—
Total	48,259	61,484	62,561	172,305	1,557	173,863
Operating profit (loss)	6,361	3,635	3,494	13,491	(4,278)	9,212
Finance income						1,414
Finance costs						3,215
Profit (loss) before taxes						7,411
Other items						
Depreciation and Amortization	3,323	4,984	5,661	13,970	340	14,310
Impairment losses	56	—	—	56	—	56

(Notes) “Others” of “Others, adjustments and eliminations” is an operating segment not included in reportable segments and “adjustments and eliminations” mainly includes eliminations of intersegment transactions and corporate expenses not allocated to each reportable segment.

Six months ended September 30, 2025

(Unit: million yen)

	Diabetes Management	Healthcare Solutions	Diagnostic & Life Sciences	Subtotal	Others, adjustments and eliminations	Consolidated basis
Revenue						
Sale from external customers	48,678	62,653	59,142	170,474	2,901	173,375
Intersegment sales	—	—	—	—	—	—
Total	48,678	62,653	59,142	170,474	2,901	173,375
Operating profit (loss)	9,328	2,970	1,317	13,616	(3,237)	10,378
Finance income						169
Finance costs						9,606
Profit (loss) before taxes						941
Other items						
Depreciation and Amortization	2,224	5,205	5,615	13,044	302	13,347
Impairment losses	—	—	1	1	—	1

(Notes) “Others” of “Others, adjustments and eliminations” is an operating segment not included in reportable segments and “adjustments and eliminations” mainly includes eliminations of intersegment transactions and corporate expenses not allocated to each reportable segment.



## Revenue

Disaggregation of revenue

Revenue disaggregation by reportable segments and major regions is as follows.

Six months ended September 30, 2024

(Unit: million yen)

	Diabetes Management	Healthcare Solutions	Diagnostic & Life Sciences	Other	Total
By region					
Japan	2,178	61,185	10,384	87	73,835
Europe	26,009	57	14,861	—	40,928
North America	10,442	58	28,510	—	39,011
Other	9,628	183	8,805	1,470	20,087
Total	48,259	61,484	62,561	1,557	173,863

Six months ended September 30, 2025

(Unit: million yen)

	Diabetes Management	Healthcare Solutions	Diagnostic & Life Sciences	Other	Total
By region					
Japan	1,802	62,352	10,015	66	74,236
Europe	26,855	151	15,827	—	42,834
North America	11,240	13	24,886	—	36,140
Other	8,779	136	8,413	2,834	20,164
Total	48,678	62,653	59,142	2,901	173,375